Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The Cyclin D2 (CCND2) mRNA 3' untranslated region (UTR) is a key regulatory element of the CCND2 gene transcript, playing a pivotal role in controlling protein expression levels through post-transcriptional mechanisms (Source: NIH/PubMed). CCND2 itself is a critical regulator of the G1/S phase transition in the cell cycle, and its precise control is essential for normal cellular proliferation (Source: UniProt P30279). The 3' UTR serves as a scaffold for the binding of microRNAs (miRNAs) and RNA-binding proteins that influence mRNA stability and translation efficiency (Source: Frontiers in Oncology). In various cancers, including mantle cell lymphoma and leukemia, the CCND2 3' UTR is frequently altered or its regulatory miRNA interactions are disrupted, leading to pathological overexpression of the Cyclin D2 protein (Source: NIH/PubMed). This makes the 3' UTR a significant target for emerging RNA-targeted therapies, such as antisense oligonucleotides (ASOs) and miRNA mimics, which aim to downregulate CCND2 expression (Source: CAS.org). Additionally, germline mutations in CCND2 or its regulatory pathways are associated with Megalencephaly-polymicrogyria-polydactyly-hydrocephalus (MPPH) syndrome, highlighting its importance in developmental biology (Source: Nature Genetics). Targeting this region offers a strategy to selectively modulate the cell cycle in hyperproliferative diseases.
RNA interference and antisense-mediated degradation or translational inhibition
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Cyclin D2 mRNA 3' untranslated region (CCND2 mRNA 3' UTR).